Abbott India Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2025
Published on 15/05/2025 at 22:05
Share
Abbott India Limited reported earnings results for the fourth quarter and full year ended March 31, 2025. For the fourth quarter, the company reported sales was INR 16,045.9 million compared to INR 14,386.3 million a year ago. Revenue was INR 16,806.1 million compared to INR 15,197.8 million a year ago. Net income was INR 3,670.4 million compared to INR 2,870.6 million a year ago. Basic earnings per share from continuing operations was INR 172.72 compared to INR 135.09 a year ago. Diluted earnings per share from continuing operations was INR 172.72 compared to INR 135.09 a year ago.
For the full year, sales was INR 64,091.5 million compared to INR 58,489.1 million a year ago. Revenue was INR 66,847.3 million compared to INR 60,971.8 million a year ago. Net income was INR 14,144.4 million compared to INR 12,012.2 million a year ago. Basic earnings per share from continuing operations was INR 665.62 compared to INR 565.28 a year ago. Diluted earnings per share from continuing operations was INR 665.62 compared to INR 565.28 a year ago.
Abbott India Limited is an India-based company engaged in the pharmaceuticals business. The Company is involved in product development, manufacturing, and sales of healthcare products. It operates in a single reportable business segment, which is Pharmaceuticals. It distributes products and solutions in multiple therapeutic categories such as women's health, gastroenterology, cardiology, metabolic disorders, Central Nervous System, Vaccines, Multi-Specialty, and primary care. Its products include Colospa (irritable bowel disease), Ganaton (gastrointestinal motility), Librax (irritable bowel disease), Thyronorm (hypothyroidism), Duphaston (miscarriage and IVF), Duphalac (constipation), Digene (antacid), Prothiaden (pain and depression), Influvac (prevention of influenza), Cremaffin Plus (Constipation), Pankreoflat (indigestion), Brufen P (fever), and Duvadilan (preterm labor). It offers various products under brands such as Similac, PediaSure, Pedialyte, EleCare, Ensure, and Glucerna.
